These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 20670950

  • 1. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
    Mizutani T, Kondo T, Darmanin S, Tsuda M, Tanaka S, Tobiume M, Asaka M, Ohba Y.
    Clin Cancer Res; 2010 Aug 01; 16(15):3964-75. PubMed ID: 20670950
    [Abstract] [Full Text] [Related]

  • 2. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M.
    Leuk Res; 2008 Apr 01; 32(4):643-9. PubMed ID: 17900686
    [Abstract] [Full Text] [Related]

  • 3. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
    Desplat V, Lagarde V, Belloc F, Chollet C, Leguay T, Pasquet JM, Praloran V, Mahon FX.
    Cytometry A; 2004 Nov 01; 62(1):35-45. PubMed ID: 15468123
    [Abstract] [Full Text] [Related]

  • 4. [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
    Xu N, Ouyang Z, DU QF, Wang S, Yang J, Wang Y, Liu XL.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan 01; 32(1):25-8. PubMed ID: 21429397
    [Abstract] [Full Text] [Related]

  • 5. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 6. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
    White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes T.
    J Clin Oncol; 2007 Oct 01; 25(28):4445-51. PubMed ID: 17906206
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 9. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.
    Cancer; 2004 Apr 01; 100(7):1459-71. PubMed ID: 15042680
    [Abstract] [Full Text] [Related]

  • 10. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C, Sattler M.
    Crit Rev Oncol Hematol; 2006 Feb 01; 57(2):145-64. PubMed ID: 16213151
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F, Shi X, Li S, Cui J, Lu Z, Jin Y, Lin Y, Pang J, Pan J.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1806-15. PubMed ID: 20149665
    [Abstract] [Full Text] [Related]

  • 12. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.
    Clin Cancer Res; 2007 Feb 15; 13(4):1089-97. PubMed ID: 17317816
    [Abstract] [Full Text] [Related]

  • 13. SH2 Domain-Based FRET Biosensor for Measuring BCR-ABL Activity in Living CML Cells.
    Fujioka M, Asano Y, Nakada S, Ohba Y.
    Methods Mol Biol; 2017 Feb 15; 1555():513-534. PubMed ID: 28092053
    [Abstract] [Full Text] [Related]

  • 14. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
    Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, Eaves C.
    Leukemia; 2007 May 15; 21(5):926-35. PubMed ID: 17330101
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.
    Haematologica; 2005 Apr 15; 90(4):534-41. PubMed ID: 15820950
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
    Patel H, Marley SB, Greener L, Gordon MY.
    Leukemia; 2008 Mar 15; 22(3):559-71. PubMed ID: 18059481
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
    Cang S, Liu D.
    J Hematol Oncol; 2008 Oct 01; 1():15. PubMed ID: 18828913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.